The 2024 Nobel prize in Medicine: impact on hemostasis and thrombosis research

Published: 19 November 2024
Abstract Views: 341
PDF: 139
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

On October 7th,  the Nobel Prize in Physiology or Medicine was awarded jointly to Victor Ambros and Gary Ruvkun for the discovery of microRNA and its role in post-transcriptional gene regulation...

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

1. Lee RC, Ambros V. An extensive class of small RNAs in Caenorhabditis elegans. Science 2001;294:862-4. DOI: https://doi.org/10.1126/science.1065329
2. Lee R, Feinbaum R, Ambros V. A short history of a short RNA. Cell 2004;116):S89-92. DOI: https://doi.org/10.1016/S0092-8674(04)00035-2
3. Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 2010;11:597-610. DOI: https://doi.org/10.1038/nrg2843
4. Landry P, Plante I, Ouellet DL, et al. Existence of a microRNA pathway in anucleate platelets. Nat Struct Mol Biol 2009;16:961-6. DOI: https://doi.org/10.1038/nsmb.1651
5. Bury L, Gresele P. The amazing genetic complexity of anucleated platelets. Bleeding Thromb Vasc Biol 2022;1:33. DOI: https://doi.org/10.4081/btvb.2022.33
6. Rowley JW, Oler AJ, Tolley ND, et al. Genome-wide RNA-seq analysis of human and mouse platelet transcriptomes. Blood 2011;118:e101-1. DOI: https://doi.org/10.1182/blood-2011-03-339705
7. Bray PF, McKenzie SE, Edelstein LC, et al. The complex transcriptional landscape of the anucleate human platelet. BMC Genomics 2013;14:1. DOI: https://doi.org/10.1186/1471-2164-14-1
8. Edelstein LC, Simon LM, Montoya RT, et al. Racial differences in human platelet PAR4 reactivity reflect expression of PCTP and miR-376c. Nat Med 2013;19:1609-16. DOI: https://doi.org/10.1038/nm.3385
9. Londin E, Loher P, Telonis AG, et al. Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-specific microRNAs. Proc Natl Acad Sci USA 2015;112:E1106-15. DOI: https://doi.org/10.1073/pnas.1505397112
10. Risitano A, Beaulieu LM, Vitseva O, Freedman JE. Platelets and platelet-like particles mediate intercellular RNA transfer. Blood 2012;119:6288-95. DOI: https://doi.org/10.1182/blood-2011-12-396440
11. Barroga CF, Pham H, Kaushansky K. Thrombopoietin regulates c-Myb expression by modulating micro RNA 150 expression. Exp Hematol 2008;36:1585-92. DOI: https://doi.org/10.1016/j.exphem.2008.07.001
12. Bianchi E, Bulgarelli J, Ruberti S, et al. MYB controls erythroid versus megakaryocyte lineage fate decision through the miR-486-3p-mediated downregulation of MAF. Cell Death Differ 2015;22:1906-21. DOI: https://doi.org/10.1038/cdd.2015.30
13. Elgheznawy A, Shi L, Hu J, et al. Dicer cleavage by calpain determines platelet microRNA levels and function in diabetes. Circ Res 2015;117:157-65. DOI: https://doi.org/10.1161/CIRCRESAHA.117.305784
14. Zampetaki A, Willeit P, Tilling L, et al. Prospective study on circulating microRNAs and risk of myocardial infarction. J Am Coll Cardiol 2012 60:290-9. DOI: https://doi.org/10.1016/j.jacc.2012.03.056
15. Liang H, Yan X, Pan Y, et al. MicroRNA-223 delivered by platelet derived microvesicles promotes lung cancer cell invasion via targeting tumor suppressor EPB41L3. Mol Cancer 2015;14:58. DOI: https://doi.org/10.1186/s12943-015-0327-z
16. Krammer TL, Mayr M, Hackl M. microRNAs as promising biomarkers of platelet activity in antiplatelet therapy monitoring. Int J Mol Sci 2020;21:3477. DOI: https://doi.org/10.3390/ijms21103477
17. Teruel-Montoya R, Rosendaal FR, Martínez C. MicroRNAs in hemostasis. J Thromb Haemost 2015;13:170-81. DOI: https://doi.org/10.1111/jth.12788
18. Teruel R, Pérez-Sánchez C, Corral J, et al. Identification of miRNAs as potential modulators of tissue factor expression in patients with systemic lupus erythematosus and antiphospholipid syndrome. J Thromb Haemost 2011;9):1985-92. DOI: https://doi.org/10.1111/j.1538-7836.2011.04451.x
19. Tay JW, Romeo G, Hughes QW, Baker RI. Micro-ribonucleic Acid 494 regulation of protein S expression. J Thromb Haemost 2013;11:1547-55. DOI: https://doi.org/10.1111/jth.12331
20. Liao YC, Wang YS, Guo YC, et al. Let-7g improves multiple endothelial functions through targeting transforming growth factor-beta and SIRT-1 signaling. J Am Coll Cardiol 2014;63:1685-94. DOI: https://doi.org/10.1016/j.jacc.2013.09.069
21. Kaczmarek JC, Kowalski PS, Anderson DG. Advances in the delivery of RNA therapeutics: From concept to clinical reality. Genome Med 2017;9:60. DOI: https://doi.org/10.1186/s13073-017-0450-0
22. Dhuri K, Bechtold C, Quijano E, et al. Antisense oligonucleotides: an emerging area in drug discovery and development. J Clin Med 2020;9:2004. DOI: https://doi.org/10.3390/jcm9062004
23. Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 2010;375:998-1006. DOI: https://doi.org/10.1016/S0140-6736(10)60284-X
24. Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med 2020;382:1507-19. DOI: https://doi.org/10.1056/NEJMoa1912387
25. Lamb YN. Inclisiran: first approval. Drugs 2021;81:389-395. DOI: https://doi.org/10.1007/s40265-021-01473-6
26. Makhmudova U, Steinhagen-Thiessen E, Volpe M, Landmesser U. Advances in nucleic acid-targeted therapies for cardiovascular disease prevention. Cardiovasc Res 2024;120:1107-25. DOI: https://doi.org/10.1093/cvr/cvae136
27. Young G, Srivastava A, Kavakli K, et al. Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial. Lancet 2023;401:1427-37. DOI: https://doi.org/10.1016/S0140-6736(23)00284-2
28. Joyce GF. The antiquity of RNA-based evolution. Nature 2002;418:214-21. DOI: https://doi.org/10.1038/418214a

How to Cite

Bury, L., Malvestiti, M., & Gresele, P. (2024). The 2024 Nobel prize in Medicine: impact on hemostasis and thrombosis research. Bleeding, Thrombosis and Vascular Biology, 3(3). https://doi.org/10.4081/btvb.2024.159

Most read articles by the same author(s)